-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Kintor Pharmaceutical Limited gets an overall score of 1/5.
| ISIN | KYG5273B1077 |
|---|---|
| Exchange | HK |
| CurrencyCode | HKD |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | -0.12 |
|---|---|
| Market Cap | 543M |
| PE Ratio | None |
| Target Price | 13.7797 |
| Dividend Yield | None |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 9939.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
